Acura Pharmaceuticals (ACUR) and King Pharmaceuticals (KG) Provide Update on Acurox NDA
More News related to ACUR
- Acura Pharmaceuticals Reports Third Quarter 2009 Financial Results
- Acura Pharmaceuticals (ACUR) and King Pharmaceuticals (KG) Provide Update on Acurox NDA
- Acura (ACUR) & King Pharmaceuticals (KG) Receive Complete Response Letter From FDA for Acurox
- Unusual 11 Mid-Day Movers 6/23: MGRM, CGEN, GRH, RJET Higher; ACUR, HALO, PCBC, MTXX Lower
- Acura Pharma (ACUR) Receives Preliminary Review Letter from FDA Related to NDA for Acurox(r)
More News related to KG
- Notable 52-Week NYSE New Highs and Lows 11/19: CAH, DCI, RX, KG, MRK, TSL Highs; SNV, WNR Low
- StockPreacher.com Issues Trading Outlook for Arena Pharmaceuticals Inc.
- King Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
- Trading Outlook for ZymoGenetics Inc. Issued by StockPreacher.com
- Wedbush Upgrades ZymoGenetics (ZGEN) to Outperform; Believe ZGEN on Track to Meet 2010 Sales Estimates
More News related to Corporate News
- Hoku Scientific (HOKU) Amends Poly Deal with Jinko Solar
- American International Group (AIG), Greenberg and Smith Settle Disputes
- Heska (HSKA) Announces Agreements with Roche for Blood Gas Product Supply/Affiliated Consumables
- AIG, Greenberg and Smith to settle all disputes
- DryShips (DRYS) Announces Exercise of Over-Allotment Option by Underwriters, Closes Convertible Senior Notes Offering for Net Proceeds of $448M
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) and King Pharmaceuticals, Inc. (NYSE: KG) announced that they met with the FDA on September 2, 2009 to discuss the FDA's June 30, 2009 Complete Response Letter regarding the New Drug Application for Acurox (oxycodone HCl and niacin) Tablets CII (NDA). The FDA and the Companies agreed to take the NDA to an FDA Advisory Committee to consider the evidence to support the potential opioid abuse deterrent effects of Acurox(R) Tablets. The FDA indicated that no new clinical trials are required at this time. The FDA has not yet set a meeting date for the Advisory Committee's review of the NDA. The Companies do not expect the meeting to be convened before the end of this year.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.26Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
